Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,983
  • Shares Outstanding, K 63,350
  • Annual Sales, $ 5,490 K
  • Annual Income, $ -50,730 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.66
  • Price/Sales 11.65
  • Price/Cash Flow N/A
  • Price/Book 2.42

Options Overview Details

View History
  • Implied Volatility 256.54% ( -105.62%)
  • Historical Volatility 105.44%
  • IV Percentile 83%
  • IV Rank 34.49%
  • IV High 675.11% on 12/13/24
  • IV Low 36.20% on 07/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 2,293
  • Open Int (30-Day) 2,125

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.21
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9200 +9.78%
on 12/16/24
1.2700 -20.47%
on 11/29/24
-0.0800 (-7.34%)
since 11/20/24
3-Month
0.4500 +124.44%
on 09/26/24
1.9891 -49.22%
on 11/11/24
+0.4860 (+92.75%)
since 09/20/24
52-Week
0.4500 +124.44%
on 09/26/24
3.2000 -68.44%
on 01/12/24
-1.7300 (-63.14%)
since 12/20/23

Most Recent Stories

More News
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CUE : 1.0100 (-0.98%)
Cue Biopharma to Present at Piper Sandler 36th Annual Healthcare Conference on Clinical and Strategic Updates

Cue Biopharma will discuss clinical updates and business strategies at the Piper Sandler Healthcare Conference on December 4, 2024.Quiver AI SummaryCue Biopharma, Inc., a clinical-stage biopharmaceutical...

CUE : 1.0100 (-0.98%)
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

CUE : 1.0100 (-0.98%)
Cue Biopharma, Inc. Reports Third Quarter 2024 Business and Financial Update, Highlighting Positive Phase 1 Trial Data for CUE-101 and CUE-102

Cue Biopharma reported positive Phase 1 trial data for CUE-101 and CUE-102, highlighting advancements in T cell modulation therapies.Quiver AI SummaryCue Biopharma, Inc. provided a business and financial...

CUE : 1.0100 (-0.98%)
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CUE : 1.0100 (-0.98%)
Cue Biopharma Announces Strategic Organizational Transition

CUE : 1.0100 (-0.98%)
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

CUE : 1.0100 (-0.98%)
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

CUE : 1.0100 (-0.98%)
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

CUE : 1.0100 (-0.98%)
Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.0100 (-0.98%)

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.1700
2nd Resistance Point 1.1300
1st Resistance Point 1.0700
Last Price 1.0100
1st Support Level 0.9700
2nd Support Level 0.9300
3rd Support Level 0.8700

See More

52-Week High 3.2000
Fibonacci 61.8% 2.1495
Fibonacci 50% 1.8250
Fibonacci 38.2% 1.5005
Last Price 1.0100
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar